Pharmacometrics

Amylyx has an audacious mission to usher in a new era for treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are a clinical-stage company currently focused on post-bariatric hypoglycemia (PBH), Wolfram syndrome, and amyotrophic lateral sclerosis (ALS).

Our mission is powered by our people. Our core values – be audacious, be curious, be authentic, be engaged, and be accountable – creating a culture of caring. Amylyx has assembled an experienced team ready to take action because the communities we serve have no time to wait. If you share our passion and are determined to tackle some of medicine’s toughest problems, we encourage you to read the opportunity below and apply.

The Opportunity

The Senior Director, Pharmacometrics will provide strategic and scientific leadership for pharmacometric activities supporting Amylyx’s clinical development portfolio. This leader will develop and execute model-informed drug development strategies across programs and stages of development, using quantitative approaches to inform dose selection, clinical trial design, regulatory strategy, and benefit-risk assessment. 

Serving as a key scientific partner to Clinical Pharmacology, Clinical Development, Biostatistics, Regulatory Affairs, Translational Medicine, and other cross-functional teams, this individual will translate complex quantitative analyses into clear, actionable recommendations for program teams and senior leadership. The role requires both strategic leadership and hands-on technical depth as programs advance toward regulatory submissions and commercialization. 

Responsibilities

• Develop and lead pharmacometrics strategies across assigned clinical development programs, aligning model-informed drug development plans with clinical and regulatory objectives.
• Lead population pharmacokinetic(PopPK), PK/PD, exposure-response, disease progression, and other quantitative modeling and simulation activities to inform dose and regimen selection, trial design, patient population selection, and interpretation of clinical data.
• Provide quantitative input into clinical development plans, protocols, statistical analysis plans, integrated development plans, regulatory strategies, and key program decisions throughout the development lifecycle.
• Support regulatory submissions and interactions, including INDs, NDAs/BLAs, briefing documents, health authority responses, and pharmacometrics or clinical pharmacology components of submission documents.
• Integrate clinical pharmacology, biomarker, efficacy, safety, and other relevant data into modeling strategies that support development recommendations and benefit-risk assessment.